Human Vascular Endothelium from Induced Pluripotent Stem Cells by Adams, William James
 Human Vascular Endothelium from Induced Pluripotent Stem Cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Adams, William James.  2013.  Human Vascular Endotheliumfrom Induced Pluripotent Stem Cells.  Doctoral dissertation,
Harvard University.
Accessed April 17, 2018 4:08:38 PM EDT
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11158273
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Human Vascular Endothelium from Induced Pluripotent Stem Cells 
 
A dissertation presented 
 
by 
 
William James Adams 
 
to 
 
The School of Engineering and Applied Sciences 
 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
 
Engineering Sciences 
 
Harvard University 
Cambridge, Massachusetts 
 
April 2013 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 William Adams 
All rights reserved.
iii 
 
Dissertation Advisor: Professor Guillermo García-Cardeña William James Adams 
 
Human Vascular Endothelium from Induced Pluripotent Stem Cells 
 
Abstract 
 
 
The vascular endothelium is a dynamic cellular interface that displays a unique phenotypic 
plasticity. This plasticity is critical for vascular function and when dysregulated is pathogenic in several 
diseases. The development of new human endothelial genotype-phenotype studies, personalized vascular 
medicine efforts and cell based regenerative therapies are limited by the unavailability of patient-specific 
endothelial cells. Induced pluripotent stem cells (iPSC) offer great promise as a new personalized source 
of endothelium; however, the reproducibility, fidelity and functionality of iPSC-derived endothelial cells 
remains poorly understood.  
In my dissertation research, I have generated vascular endothelium from human iPSC and 
systematically evaluated their potential for endothelia-specific functionality in order to begin establishing 
iPSC as a new cellular platform for studying endothelial cell biology. I have reproducibly differentiated 
iPSC into vascular endothelium exhibiting the functional phenotypic plasticity of mature primary cultured 
vascular endothelium. These endothelial cells respond to diverse pro-inflammatory stimuli, adopting an 
activated phenotype including leukocyte adhesion molecule expression, cytokine secretion and support of 
leukocyte transmigration. They maintain dynamic barrier properties responsive to multiple vascular 
permeability factors. Importantly, to demonstrate that iPSC-derived endothelial cells are capable of 
acquiring pathophysiologically-relevant phenotypes critical for modeling human vascular disease, I 
probed the response of these cells to biomechanical or pharmacological stimuli. 
The endothelium derived from iPSC is unique for its lack of an anatomical site of origin and lack 
of exposure to blood flow. I observed that distinct endothelial cell subpopulations expressing arterial or 
venous endothelial cell markers are created by differentiating iPSC. I also demonstrated that while some 
molecular aspects of these identities are specified by genetic programs initially, the endothelial identity is 
plastic and also can be modulated by biomechanical forces. These results suggest iPSC can yield arterial 
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and venous endothelium in the absence of flow; but the fate of iPSC endothelial cells in culture is also 
sensitive to the de novo application of biomechanical forces. 
 My results demonstrate iPSC-derived vascular endothelium possesses a repertoire of functional 
phenotypic plasticity, and is amenable to cell-based assays probing the endothelial contributions to 
inflammatory and cardiovascular diseases. 
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1 | Introduction to the study of the vascular endothelium 
 
1.1 | Human vascular endothelium and its study in vitro 
 
The vascular endothelium is the single-cell layer lining blood vessels that forms an interface 
between circulating blood and other tissues. Endothelial cells constitute a multifunctional interface that 
displays a striking phenotypic plasticity necessary for maintaining vascular homeostasis. In this context, 
the vascular endothelium is critical to initiate an inflammatory response, trigger thrombosis, regulate 
vasomotor tone and control vascular permeability. Dysfunction of the endothelium plays a significant 
pathogenic role in cardiovascular diseases, namely, atherosclerosis and its consequences heart attacks and 
strokes. In addition, genetic mutations in proteins expressed by endothelial cells lead to multiple types of 
vascular malformations1,2. Today, studies at the genetic and molecular level of human endothelium have 
been limited by the availability of relevant tissue derived from cadaveric, discarded surgical or umbilical 
vasculature sources. 
The cellular layer lining blood and lymph vessels was first given the name endothelium by 
Wilhelm His in 1865 as he was describing mesodermal development in the chick embryo3. During the 
century that followed, the structure and function of the vascular endothelium was studied primarily 
through histological and ultrastructural methodologies applied to various model organisms or pathological 
or cadaveric human tissue. In the early 1970s, the process of isolation of human umbilical cord vein 
endothelial cells was developed and, critically, the conditions necessary to maintain human endothelial 
cell growth in vitro were defined4,5. This foundational work allowed extensive controlled in vitro studies 
which over the last 30 years have defined the scientific and medical community’s understanding of the 
vascular endothelium as fulfilling the diverse functional roles critical for vascular homeostasis mentioned 
above. 
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In the decade following the isolation and culture of primary human endothelial cells, advances in 
mammalian embryology permitted the isolation and in vitro culture of mouse embryonic stem cells6,7. 
These stem cells exhibited the pluripotency of the developing embryo such that they can differentiation 
into all cell types of the organism. As these differentiation processes were studied, they were soon 
harnessed to permit in vitro differentiation of murine embryonic stem cells into mature cell types 
including vascular endothelium8. Almost two decades after murine stem cell lines were generated, human 
embryonic stem cells were isolated from discarded human embryos created by in vitro fertilization9 and 
within a few years were able to be experimentally manipulated to produce human vascular endothelium 
through in vitro differentiation10. Embryonic stem cells offered practical experimental convenience: the 
ability to generate vascular isogenic endothelial cells from pluripotent progenitors on demand without the 
often tedious and inefficient necessity of isolating endothelial cells from heterogeneous tissue samples 
and the even requirement of procuring discarded tissues in the first place. However, the challenge that 
embryonic stem cell derived endothelium presents is the uncertainty of the fidelity of in vitro stem cell 
derived tissues to their primary cell analogs in addition to more practical concerns such as reproducibility, 
cost and time.  
Beyond the generation of human vascular endothelial cells to study endothelial cell biology, the 
genetic revolution at the end of last century created demand for endothelial cells with particular genetic 
backgrounds to study the functional implications of various disease-associated mutations or 
polymorphisms in genotype-phenotype studies. It is possible for stem cell lines to be generated from 
human embryonic stem cells with approximately half of a patient’s particular genetic background. This 
technology is technically cumbersome, expensive and necessitates the ethically controversial creation and 
destruction of fertilized human embryos, all of which limit the proliferation of personalized stem cell lines 
and hence personalized vascular endothelium. Further, cell lines incompletely representing a desired 
genetic background may not aid in genotype-phenotype studies nor constitute a new cellular source for 
regenerative medicine. Alternatively, it is theoretically possible to crease pluripotent stem cell lines with 
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complete genetic fidelity to a donor via cloning or somatic cell nuclear transfer, though this has yet to be 
accomplished in humans. 
Recently, the discovery of cellular reprograming as a technology to generate induced pluripotent 
stem cells (iPSC) offers a potential solution to the challenge of limited cardiovascular cell sources. In this 
approach, human adult somatic cells, commonly dermal fibroblasts or hematopoietic cells, are de-
differentiated into pluripotent stem cells offering comparable function to human embryonic stem cells in 
their ability to develop differentiated progeny from all developmental lineages in the organism. Human 
induced pluripotent stem cells were originally derived by retroviral mediated overexpression of four 
transcription factors, Oct4, Sox2, Klf4 and c-myc, observed to be present and essential in human 
embryonic stem cells11. However, since this seminal discovery, numerous alternative strategies for 
derivation have been discovered and validated, some involving integration of exogenous factors into the 
genome and some without any genome modification, as reviewed elsewhere12. The methodology to 
achieve reprogramming of adult human somatic cells to pluripotency will no doubt continue to be a 
subject of great academic and commercial interest with efficiency, speed and reproducibility to improve. 
This technology enables the scientist to choose the particular patient source and hence corresponding 
genetic background for further study or screening. This patient sample is induced to pluripotency, and 
subsequently directed to differentiate into the desired cell type. Significantly, these human iPSC are 
infinitely expandable in their pluripotent form, are generated from minimally-invasive tissue sampling 
and lack the ethical concerns surrounding manipulation of the human embryo as in embryonic stem cell 
derivation. It is believed that as iPSC are able to be generated easily from patients, they will constitute a 
valuable resource for understanding the pathological molecular mechanisms underlying genetic disorders, 
provide substrate for novel drug discovery and enable various regenerative medicine technologies as a 
cell based therapy. 
In order to be useful for modeling cardiovascular disease and participating in the drug discovery 
process, iPSC need to be differentiated into cell types relevant for various cardiovascular diseases, 
namely, endothelium, smooth muscle, cardiac myocytes, fibroblasts as well as hematopoietic lineage cell 
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types known to participate in vascular disease pathogenesis such as monocytes, lymphocytes and 
thrombocytes. There has been some progress in generating such cardiovascular disease relevant cell 
types. In general, this was accomplished either through the formation of differentiating heterogeneous 
three-dimensional embryoid bodies from which a cell type may be isolated, as exemplified within Figure 
1.1, or though addition of various factors to encourage pluripotent colonies to differentiate along a 
specific lineage. In particular, human iPSC within various in vitro contexts have been differentiated into 
endothelium13-19. Despite these reports, which describe the emergence of cell populations largely bearing 
molecular markers of the desired cell type, there is a paucity of functional characterization of the 
differentiated cell types. There are still significant unanswered questions about the character of the iPSC 
derived vascular cells, namely, whether they faithfully represent the mature phenotype and can perform 
the many dynamic functions of adult vascular cell types offering a surrogate model system for human 
primary cells. This functionality must be carefully assessed before their scientific and therapeutic 
potential can be realized20. 
 
Figure 1.1 | Illustration of the process of generating endothelial cells 
from patient tissue samples via induced pluripotent stem cells.  
At the outset of the study presented here, there existed only limited characterization of 
endothelia-specific functions within iPSC derived endothelium. Several groups have used human iPSC to 
generate endothelial cells and multiple reports describe the presence of endothelial protein markers by 
flow cytometry or immunofluorescence imaging, uptake of acetylated-LDL or the capacity to form 
networks when cultured on matrigel in vitro with iPSC endothelial cells13-16,18,19,21. One of these groups 
has demonstrated that subcutaneous implantation of a matrigel plug seeded with iPSC endothelial cells 
into immunocompromised mice results in the formation of erythrocyte-containing vascular networks after 
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2 weeks14. Additionally, two reports described that injection of human iPSC derived endothelial cells into 
immunocompromised mice with hind limb ischaemia induced by femoral artery ligation resulted in 
ameliorated peripheral perfusion15,17. In these three studies, the exogenous cells were shown to associate 
with the host vasculature; however, no cellular function was measured in the injected human endothelial 
cells. In fact, in these reports the regenerative effect of enhanced peripheral tissue perfusion was 
principally ascribed not to incorporation of human endothelial cells into the mouse vascular bed but to a 
paracrine effect of stimulating the existing vasculature to proliferate. 
Despite these initial reports, it was previously unexplored whether human iPSC derived vascular 
endothelial cells are capable of complex physiological functions such as participating in the inflammatory 
response, initiating thrombosis, maintaing a dynamic barrier and responding to biomechanical 
stimluation, functions critical for maintaining vacular homeostasis. Elucidation of whether iPSC derived 
endothelium can display endothelia-specific functions is essential for applying iPSC endothelium to 
disease modeling. Hence, two of the goals of this study were to first reproducibly generate human iPSC-
derived vascular endothelial cells (iPSC-EC) and, second, to then assess whether they could acquire 
specific functional phenotypes displayed by primary cultures of human vascular endothelium.  
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1.2 | Specification of vascular endothelium to arterial and venous fates 
 
While all blood vessels are lined with a single cell layer of vascular endothelial cells, there exists 
significant heterogeneity amongst these endothelial cells depending on their anatomical location22-27. 
Hierarchy amongst blood vessels and anatomical differences between arteries and veins were first 
described by the fourth century BC physician Herophilos28. The modern conception of the circulatory 
system including the idea of a closed connect circuit with the contemporary directionality of blood flow 
would be described two thousand years later by William Harvey in his “De motu cordiis”29. The two most 
eminent categorizations of vascular endothelium in blood vessels are arterial and venous subtypes; 
however there are also microvascular endothelial cells as well as organ-specialized endothelium such as 
the blood brain barrier, kidney glomerular endothelium and liver sinusoidal endothelium. While there are 
additional hierarchies and dimensions of heterogeneity depending on the diameter of the blood vessel and 
also the local hemodynamic environment established by blood flow and the local vessel geometry, the 
variations between arterial and venous subtypes have been best characterized at the molecular level30-34. 
The ability of human iPSC derived vascular endothelium to acquire arterial and venous fates has been 
largely unexplored. Only during the writing of this dissertation was the first report published describing 
the presence of arterial and venous specific markers within a mixed heterogeneous pool of iPSC derived 
endothelium, though without isolating and purifying specific arterial or venous endothelial cells35.  
In order to generate vascular endothelial cells from human iPSC and further to specify them into 
arterial and venous fates, it is important to consider this synthetic in vitro differentiation process in 
relation to physiological human vascular development. In particular, one element of physiological 
development strikingly absent from in vitro differentiation is the presence of cardiac driven circulation 
and hence hemodynamics derived physical forces. It has long been known that biomechanical forces 
influence the vascular system during embryonic development. Such influence centered around two 
archetypical interactions: first, hemodynamic forces can alter the geometry of vascular networks, and 
second, hemodynamic forces can modify the arterial or venous identity of vascular endothelial cells. 
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There are numerous examples of how circulatory blood flow influences vessel geometry. For 
instance, within zebrafish expressing the silent heart mutation (in a gene encoding a cardiac myocyte 
troponin) which precludes cardiac contraction, the gross architecture of their arteries and veins develops; 
however, the lack of hemodynamic forces during development causes morphological and connectivity 
changes in secondary and tertiary vessel patterning36. Similarly, remodeling of the mouse yolk sac 
vasculature fails to develop proper vessel hierarchy from an initial plexus in embryos lacking circulation 
in both myosin light chain 2c knockouts37 and sodium-calcium exchanger 1 knockouts38. 
In addition to influencing blood vessel network morphology, hemodynamic forces have been 
shown to affect the identity of vascular endothelium at the molecular level. In fact, multiple studies have 
described how the arterial or venous identity of vascular endothelial cells is able to be modified by 
hemodynamic forces both during embryonic development and during adulthood. For instance, quail 
arterial endothelial cells are able to integrate into chicken embryonic venous vasculature and express 
venous molecular markers while quail venous endothelial cells incorporate into arterial vessels and 
express arterial specific markers as a result of local hemodynamic forces39. Further, manipulation of the 
chick embryo vitelline vasculature by incision or ligation altering blood flow can influence the identity of 
the yolk sac vessels into arterial or venous following induction of arterial or venous flow respectively40. 
Transplantation of venous segments into the arterial tree of developing chick embryos induces the 
expression of ephrin-B2, a faithful marker of arterial endothelial identity41. This plasticity of vascular 
endothelial identity is not limited to the embryonic vasculature. It is commonly observed that when 
transplanting human venous segments into the arterial tree as commonly performed in coronary or 
peripheral artery bypass grafting, or in the gross alteration of blood flow such as in the artificial creation 
of arterial-venous fistulas, that the venous endothelium now exposed to an arterial hemodynamic 
microenvironment remodels and arterializes42. Several aspects of this arterialization can be replicated in 
vitro by exposing cultured primary human venous endothelial cells to arterial hemodynamic forces 
resulting in upregulation of arterial specific endothelial gene expression. 
8 
 
Although multiple observations demonstrated that there exists plasticity within the vascular 
endothelial arterial or venous identity subject to hemodynamic environment, new evidence arose 
describing the genetic specification of vascular endothelial fate. In 1998, Wang et al reported that 
embryonic murine vasculature selectively expresses the transmembrane ligand ephrinB2 on arterial 
endothelial cells and its cognate receptor EphB4 on venous endothelial cells prior to the onset of cardiac 
contraction, blood circulation and hence hemodynamic forces on the vascular wall43. This impressive 
observation demonstrated that arterial and venous endothelial cells initially exhibit molecular distinction 
through genetic developmental programs and not as a consequence of their biomechanical environment34. 
Subsequently, it was demonstrated that this early embryonic molecular distinction persists through 
development and post natal life44. Further, it has been reported that arterial and venous endothelial cells 
forming the first artery and vein in zebrafish arise from distinct angiogenic precursors45. 
 As the ability to produce endothelium with arterial or venous identity from human iPSC has 
numerous applications for disease modeling and pharmacological testing, as will be explored in Chapter 
6, the third goal of this dissertation is to isolate and characterize these specific endothelial subtypes. 
Specifically, as motivated by these previously published observations in the literature regarding 
endothelial specification, I sought to evaluate whether arterial and venous endothelium develops via 
genetic programs independent of hemodynamic condition and also whether distinct hemodynamic stimuli 
are able to affect endothelial specification.  
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1.3 | Specific aims of this dissertation 
 
 
 
Specific Aim 1 | Develop a robust and reproducible methodology to generate vascular endothelial cells 
from human induced pluripotent stem cells 
 
Specific Aim 2 | Evaluate endothelia-specific functionality in induced pluripotent stem cell derived 
endothelial cells 
 
Specific Aim 3 | Examine the ability of human induced pluripotent stem cell derived endothelium to 
adopt arterial and venous specific identities 
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2 | The derivation of vascular endothelium from human induced 
pluripotent stem cells  
 
2.1 | Differentiation of human induced pluripotent stem cells into vascular endothelium 
In order to establish iPSC as a reliable source of vascular endothelium, several fundamental 
points needed to be addressed. While human iPSC have been shown to produce endothelial cells, the 
kinetics, purity, fidelity and reproducibility of endothelial differentiation within the spontaneously 
differentiating cell populations were not characterized. The following experiments sought to address these 
points, which are prerequisite for further use of iPSC endothelium as a practical experimental platform. 
Human iPSC lines are able to be maintained in culture where they retain their undifferentiated 
pluripotent state and indefinitely self-renew under particular conditions as previously reported (see 
section 5.1). Figure 2.1 presents a phase contrast image of a single colony of hundreds of iPSC (BJ1 
iPSC line) growing on a feeder layer of mouse embryonic fibroblasts in their pluripotent state, in the 
presence of defined serum and high concentrations of bFGF. To induce differentiation and produce 
vascular endothelial cells, I differentiated human iPSC as embryoid bodies in suspension by physically 
lifting iPSC colonies from their substrate with a cell scraper and replacing the iPSC medium containing 
bFGF with differentiation medium containing 20% fetal calf serum. Complete details of the constituents 
of the media are given in Section 5.1. The specific serum chosen was selected from a screen optimizing 
proliferation and morphology of cultured human EC (previously performed by Ms. Kay Case, Brigham 
and Women’s Hospital). During the course of my studies, I have used fetal calf serum produced from 
three different lots from the same vendor. There were no obvious inter-lot variations in the endothelial 
differentiation of iPSC. These differentiation culture conditions induced the iPSC to exit their pluripotent 
phase and begin differentiation into multiple cell types. As time passes and the embryoid bodies 
differentiate, they grow in large cystic spheroidal formats which can be observed by phase contrast 
microscopy as in Figure 2.2 or alternatively seen by the unassisted eye in the culture dishes. This process 
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produces a heterogeneous population of presumably multiple cell types. To assess the time scale of when 
the differentiating embryoid bodies exit their pluripotent states and whether endothelial cell 
differentiation occurs, I performed quantitative real-time Taqman PCR (RT-PCR) using RNA harvested 
daily from whole embryoid bodies from the time of their generation from iPSC colonies (day 0) through 
18 days of differentiation. Under these conditions, I observed a loss of expression of the transcription 
factors Oct4 and Nanog, known to be critical for maintaining pluripotency46, expression of brachyury 
suggesting differentiation through mesodermal germ layer lineage47, expression of the developing 
hemangioblast transcription factor Gata248 and finally increasing expression of endothelial cell markers 
VE-cadherin (VEC), KDR (VEGFR2) and CD31 (also known as PECAM1) (Figure 2.3). This gene 
expression analysis suggested that the embryoid bodies lost the transcriptional controls of pluripotency 
within a week and that endothelial cell development is occurring within approximately 7-14 day time 
frame. However, such analysis offers a crude perspective as the expression levels of such genes are 
averaged across several different cell types. There are several potential sources of heterogeneity in this 
differentiation process. There could be inter-embryoid body variation in the magnitude of endothelial cell 
differentiation. It is also possible that not all embryoid bodies are synchronized with respect to their 
developmental time. While the initial size of the embryoid body may be an important influence on its 
differentiation potential, it is difficult to precisely control the geometry during embryoid body formation. 
It is also likely that with small numbers of cells there exist stochastic processes dictating cell 
differentiation decisions into the three germ layers and more mature cell types which may be influence by 
local cues difficult to control. To better define the presence and quantity of the putative endothelial cell 
population which is suggested by the qRT-PCR results, I measured the cell surface protein expression of 
endothelial cell markers VEC, CD31 and KDR with flow cytometry within dissociated embryoid bodies 
after different durations of differentiation. As seen in Figure 2.4, after 10 days of differentiation, a 
VEC+/CD31+ endothelial cell population peaked at 18% ± 4% (mean ± s.d.) as the KDR+/CD31+ 
population was 14.7% ± 4% (mean ± s.d.) of the embryoid body. To visualize the presence of endothelial 
cells within the intact embryoid body with approximately 1 mm diameter on day 10, I used two photon 
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confocal microscopy with immunofluorescent-labeled VEC which illustrated that most VEC+ cells reside 
in network structures (Figure 2.5). While this differentiation process from iPSC into vascular endothelial 
cell was reproducible within the iPSC line tested (BJ1 cell line), I investigated whether such in vitro 
endothelial differentiation is robust and generalizable to other human iPSC lines. To confirm this, I 
evaluated the endothelial differentiation potential of several other iPSC lines derived from different 
laboratories, from different donor cell types and generated through different induced pluripotency 
reprogramming technologies (see section 5.1 for details regarding each line). Each of the 4 lines tested 
was reproducibly capable of producing endothelial cells as measured by the presence of VEC expressing 
cells by flow cytometry after 10 days of differentiation; however, the fraction of VEC+ cells differed 
between the lines (Figure 2.6). Due to its high yield of endothelial cells, the cell line BJ1 generated from 
human foreskin dermal fibroblasts by the overexpression of Oct4, Sox2, KLF4 and c-myc (the so called 
Yamanaka factors) by four retroviruses was utilized for analysis in subsequent experiments described in 
the following sections. 
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Figure 2.1 | Phase contrast image of a colony of human induced 
pluripotent stem cells in their pluripotent state cultured on a feeder 
layer of mouse embryonic fibroblasts.  
 
Figure 2.2 | Phase contrast images showing temporal profile of 
spontaneously differentiating iPSC as embryoid bodies acquired 
after various durations of differentiation.  
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Figure 2.3 | Temporal profiles of gene expression of indicated genes 
in spontaneously differentiating embryoid bodies after different 
durations of differentiation as measured by qRT-PCR. Error bars 
indicate standard errors, n=3. * indicates p < 0.05 comparing 
indicated mean to the baseline undifferentiated day 0 mean. 
 
  
15 
 
 
Figure 2.4 | Temporal profile of the fraction of embryoid body cells 
comprised of CD31+, VEC+, VEC+/CD31+, KDR+/CD31+ cell 
populations as measured by flow cytometry. Error bars indicate 
standard errors, n=3. 
 
 
Figure 2.5 | Reconstruction of three dimensional two-photon 
confocal microscopy images within an intact day 10 embryoid body 
with immunofluorescent labeled VE-cadherin (green) and nuclei 
(blue). VE-cadherin expressing endothelial cells grow in vessel-like 
networks in the developing embryoid body. 
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Figure 2.6 | Four different iPSC lines were used to generate 
embryoid bodies. The fraction of day 10 embryoid bodies expressing 
VE-cadherin was measured by flow cytometry. Error bars are 
standard deviation, n=3-4. * indicates a statistically different mean 
from MSC with p < 0.01 and † indicates a statistically different mean 
from BJ1 with p < 0.01. 
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2.2 | Isolation of the vascular endothelial population  
After understanding the reproducibility and dynamics of the temporal profile of endothelial 
differentiation from the embryoid bodies, the next step I undertook was to develop a protocol to isolate a 
purified endothelial cell population from the heterogeneous embryoid bodies. After this isolation, I 
subcultured this endothelial population in vitro for further characterization and downstream applications. 
The following experiments describe the optimization process for isolating and subculturing vascular 
endothelial cells from the embryoid body for further analysis. 
I choose to isolate endothelial cells from the embryoid body on day 10 of differentiation as the 
VEC+/CD31+ population peaks at day 10, providing sufficient yield of endothelial cells, high purity of 
endothelial cells in the presorted population and practicality of limiting the duration of experiments. 
Previous studies have differentiated human pluripotent stem cells and isolated endothelial cells based on 
cell surface expression of CD31, CD34, or KDR antigens13-19. In contrast, I choose to isolate endothelial 
cells from the embryoid body based on VEC expression, the most definitive marker of endothelial 
identity, as I observed the presence of putatively non-endothelial CD31+, and KDR+ cells that did not 
express VEC within the embryoid body (Figure 2.7, left and center panel). While isolation based upon 
multiple markers is desirable, I observed poor survival based on plating efficiency after fluorescence 
assisted cell sorting while magnetic bead based separation improved viability. Dissociated embryoid 
bodies were exposed to mouse IgG1 anti-VEC phycoerythrin-conjugated antibody then washed and 
exposed to magnetic bead conjugated anti- phycoerythrin antibody. Following this, the cells were passed 
through a positive selection magnetic bead assisted cell sorting (MACS) column according to 
manufacturer’s instructions (Miltenyi). Magnetic bead sorting produced a population with 95% ± 3.7% 
(mean ± s.d., n=4) VEC+ cells (Figure 2.7, right panel).  
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Figure 2.7 | Endothelial population labeled with CD31, VEC and 
KDR visualized by flow cytometry before sorting (left) and labeled 
with VEC after magnetic bead sorting (right). 
 
Before endothelial cell isolation, the large embryoid bodies must be dissociated into single cells 
for labeling and sorting. The development of a protocol to isolate iPSC derived endothelial cells began 
based on a previously published method for the dissociation of human embryonic stem cell derived 
embryoid bodies for hematopoietic cell harvesting49. This protocol called for the enzymatic dissociation 
of the embryoid bodies yet following this protocol resulted in incomplete digestion of the iPSC embryoid 
bodies after the specified two hours of enzymatic treatment. To optimize this methodology for iPSC 
derived embryoid bodies and for endothelial cell harvesting, I screened a panel of enzymes for their 
ability to efficiently dissociate the embryoid bodies into single cells. The embryoid bodies were washed 
with PBS+ then treated for 2 hours at 37°C agitated in a table top shaker at 1100 rpm with one of several 
different enzyme treatments: collagenase-dispase (Roche), Cell Dissociation Buffer (Invitrogen), Liberase 
(five different variants: TL, TM, DL, DH, TH, all from Roche), dispase (Roche), collagenase IV 
(Invitrogen), collagenase B (Roche) and dispase-DNAse (Roche and Invitrogen). After enzymatic 
treatment, the slurry was washed with PBS- then treated with enzyme-free Cell Dissociation Buffer 
(Invitrogen) for 20 min at 37°C shaking at 1100 rpm. After this step, I triturated the slurry with a P1000 
pipette tip and passed it through a 70µm then 40µm mesh filters. To select the most efficient enzyme, I 
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analyzed the filtered slurries by flow cytometry. I created a Dissociation Index defined as the product of 
the fraction of flow cytometry events contained within each of the three gates in Figure 2.8A to be able to 
quantify the effects of the enzyme on dissociating the embryoid body into single viable endothelial cells. 
Specifically, these gates select events of the size of cells on forward and side scatter dimensions that are 
alive and exclude propidium iodide, and express VEC. The product of these fractions should estimate the 
yield of VEC+ cells following enzymatic dissociation for a given starting population. The value of this 
Dissociation Index for the enzyme panel is shown in Figure 2.8B. I selected the four enzymes with the 
highest Dissociation Index values, repeated the embryonic body dissociation then followed by sorting the 
filtered slurry for VEC+ cells with magnetic bead sorting to ensure that the endothelial fraction remains 
viable after being passed through the sorting column (Figure 2.8C). This optimization process identified 
2 mg/mL collagenase B as the best candidate for enzymatic digestion of the embryoid bodies; hence, it 
was used for the remainder of the following experiments. In general, independent experiments were 
defined as independent differentiations spanning 10 days and isolations beginning from a different batch 
of iPSC. 
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Figure 2.8 | (A) Gating of dissociated embryoid bodies showing the 
three flow cytometry gates comprising the Dissociation Index. (B) 
The value of the Dissociation Index for a panel of enzymes after 
dissociating embryoid bodies before sorting. Error bars indicate 
standard deviations, n=3. (C) Dissociation Index values in the VEC+ 
magnetic bead sorted population for selected enzymes. 
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After dissociation and magnetic bead based isolation, the purified VEC+ endothelial cell 
population was plated into in vitro culture. Initially, I attempted to culture the iPSC derived vascular 
endothelial cells on gelatinized (0.1% gelatin) tissue culture plastic surfaces following the protocol 
typically used for human umbilical vein endothelial cell culture in our laboratory; however, I noticed poor 
cell spreading immediately after plating and large numbers of cells delaminating within the first 24 hr 
after seeding. This observation suggested that the in vitro culture conditions, perhaps the extracellular 
matrix of 0.1% gelatin, was not be ideal for iPSC derived endothelial cell growth. To evaluate other 
extracellular matrices, I isolated VEC+ cells and cultured them using a Millicoat ECM Screening Kit 
(Millipore, Billerica, MA) which provides a standard multiwell plate with surface pre-coated surfaces 
with several different cell matrix proteins. Out of the matrices provided (fibronectin, collagen I, collagen 
II, collagen IV, laminin, vitronectin, tenascin and bovine serum albumin), only the fibronectin coated well 
exhibited any adhesion and spreading in cells 4 hr after plating (Figure 2.9). Following this initial 
observation, I sorted the VEC+ cells onto tissue culture plastic surfaces that I plasma treated to enhance 
protein adsorption and coated with 50 µg/mL of human serum fibronectin with volume equivalent of 2.5 
µg fibronectin / cell culture area cm2 overnight at 37°C which vastly improved spreading compared to the 
commercial kit. Following this procedure, dissociating with collagenase B, using magnetic bead based 
sorting and plating onto self-made fibronectin surfaces at 20,000 cells/cm2, produced a robust protocol for 
the isolation of VEC+ endothelial cells from iPSC. Figure 2.10 presents a phase contrast image of one 
such isolation after 3 days of culture. This procedure was used to isolated endothelial cells from embryoid 
bodies for all the following experiments. 
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Figure 2.9 | Evaluation of iPSC endothelial cell spreading on various 
matrices 4 hours after magnetic bead sorting of dissociated 
embryoid bodies for VEC+ cells and plating. 
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Figure 2.10 | VEC+ endothelial cells isolated from embryoid bodies, 
purified with magnetic bead sorting and cultured on fibronectin for 
3 days. 
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3 | The functional phenotypes of human induced pluripotent stem cell 
derived vascular endothelium 
 
3.1 | Characterizing endothelial identity by molecular characteristics and behavior 
 
After I developed and validated a robust protocol to generate purified VEC+ cells derived from 
human iPSC, I sought to evaluate whether these VEC+ cells bear basic molecular and functional fidelity 
to primary human endothelium which is a precondition for their use in patient specific cell based models 
of endothelial function. Hence, I assessed whether isolated iPSC endothelial cells exhibit the expression 
of characteristic endothelial markers and behavior after in vitro culture following isolation from embryoid 
bodies. Endothelial cells were plated and cultured for 3 days (passage 1) after which characterization was 
performed. As seen in Figure 3.1, iPSC endothelial cells displayed typical cobble-stone morphology, 
expressed VEC and CD31 at cell junctions and endothelial nitric oxide synthase (eNOS) at the 
perinuclear region and plasma membrane as seen by immunofluorescent imaging. This observed 
subcellular localization of eNOS is similar to the compartmentalization of eNOS in intact human vessel 
endothelium where eNOS is known to localized to the Golgi complex and with plasmalemmal caveolin-
150,51. Further, the cell surface expression of VEC, KDR and the anti-thrombotic thrombomodulin on the 
iPSC endothelial cells is nearly uniform as measured by flow cytometry plotted in Figure 3.2. 
The endothelial glycocalyx is a large ~0.5 µm thick complex heterogeneous extracellular 
organelle between the endothelial plasma membrane and the vessel lumen. This structure consists of a 
network of glycoproteins and associated integral carrier proteins52,53. The endothelial glycocalyx is 
believed to play a role in vascular permeability, transendothelial cellular transmigration and given its 
integration with the cytoskeleton and position at the interface between the moving blood in the vessel 
lumen and the stationary endothelial cell is hypothesized to be a mechanosensor. I investigated whether 
the iPSC derived endothelium expressed several protein constituents of the glycocalyx. I observed that the 
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glycoproteins heparan sulfate and chondroitin sulfate as well as the carrier proteins syndecans-1,2 and 4, 
glypican-1, and CD44 are expressed on the surface of the iPSC endothelial cells as measured by flow 
cytometry (Figure 3.3). It has been observed that the expression levels of glycocalyx proteins is 
influenced by shear stress in vitro54,55 and correlates with shear stress levels in vivo56,57. It has also been 
observed that the there is a fibrous extracellular glycocalyx structure present in the embryonic quail dorsal 
aorta and heparan sulfate and chondroitin sulfate in the murine yolk sac at the same developmental time 
as the onset of circulation58. These observations suggest that the development of the glycocalyx is 
dependent on the biomechanical stimulation. My results with human iPSC derived endothelium suggest 
that blood flow is not necessary for the initial surface expression of the various protein constituents of the 
glycocalyx, though it may likely later influence their expression and assembly into the mature glycocalyx 
layer. 
 I also evaluated several behaviors of vascular endothelial cells typically observed within in vitro 
culture. Vascular endothelial cells are known to avidly uptake acetylated low density lipoprotein 
(AcLDL) particles via scavenger receptor mediated endocytosis59,60. I assessed whether iPSC-EC exhibit 
this capability by exposing the cells to 10 µg/mL of fluorescently labeled acetylated low density 
lipoprotein (DiL-AcLDL) in culture supernatant for 5 hrs. The iPSC endothelium endocytosed the DiL-
AcLDL particles producing a punctate patterning observed by immunofluorescent imaging (Figure 3.4B) 
suggesting cytoplasmic vesicular internalization of the particles. Flow cytometry indicated that nearly the 
entire population of endothelial cells had internalized the labeled AcLDL (Figure 3.4C). 
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Figure 3.1 | (A) Phase contrast image of iPSC endothelium. 
Immunofluorescent stain of (B) VEC, (C) eNOS and (D) CD31  
 
 
 
Figure 3.2 | Expression of VEC, KDR and thrombomodulin on the 
iPSC endothelial cell surface measured by flow cytometry.  
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Figure 3.3 | Expression of extracellular glycoproteins and carrier 
proteins comprising the endothelial glycocalyx measured by flow 
cytometry. 
 
 
 
Figure 3.4 | (A) Phase contrast image of cultured iPSC endothelium. 
(B) Fluorescent image of internalized DiL-conjugated acetylated-
LDL in punctate appearance. (C) Uniformity of acetylated-LDL 
uptake measured by flow cytometry; DiL-AcLDL untreated (black) 
and treated (red). 
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 One of the fundamental functions of the vascular endothelium is to develop new blood vessels 
from existing ones. This process is controlled through local balance of pro- and anti-angiogenic factors, 
pathways and genes. There are several methodologies to assess angiogenic potential within cultured 
endothelial cells generally fitting into two categories: network formation on two dimensional extracellular 
matrix61 or sprouting from a carrier through a three dimensional matrix62. As seen in Figure 3.5, when 
cultured on matrigel or matrigel when in the presence of 35 ng/mL bFGF or 50 ng/mL VEGF, the iPSC 
endothelial cells assembled into a network formation. This capability may be important for several of the 
putative applications of iPSC vascular endothelium both explored in section 6.2: angiogenic cell based 
therapy and genetic disease modeling. 
 
 
Figure 3.5 |  Phase contrast images of networks formed after culture 
on low-serum matrigel in the presence of 35 ng/mL bFGF or 50 
ng/mL VEGF after 6 hr. 
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3.2 | Characterization of functional Weibel-Palade Bodies 
 
The initiation of thrombosis, the coagulation of blood, is a critical function of vascular endothelial 
cells. A principal component of this physiologic process is the attachment of platelets to the endothelium 
following vascular injury mediated by endothelial von Willebrand Factor (vWF). Endothelial cells 
synthesize vWF and store the large multimeric glycoprotein within endothelia-restricted intracellular 
storage granules termed Weibel-Palade Bodies63. Production of Weibel-Palade Bodies is an essential 
component of the hemostatic and thrombotic function of vascular endothelium and not previously 
explored in endothelial cells derived from human iPSC. In order to assess the presence of these organelles 
in iPSC-EC, I investigated with immunofluorescence imaging whether iPSC derived endothelium 
expresses vWF and another protein known to be stored in Weibel-Palade Bodies, angiopoietin-264. These 
experiments revealed, as shown in Figure 3.6A and B, that both vWF and angiopoietin-2 are present in 
iPSC endothelium in a punctate pattern suggesting their localization in Weibel-Palade Bodies as in 
primary endothelium. To verify these observations, I examined the ultrastructure of iPSC endothelial cells 
by transmission electron microscopy and observed electron-dense striated structures with morphology 
characteristic of Weibel-Palade Bodies65-67 as seen in micrograph in Figure 3.6C. I also confirmed that 
these Weibel-Palade Bodies identified by electron microscopy contain vWF by observing immunogold 
particle-labeled vWF localized to these structures as in Figure 3.6D. Functionally, Weibel-Palade Bodies 
store and rapidly exocytose their cargo including vWF and P-Selectin to initiate a hemostatic 
response68,69. Thus, in order to verify that the Weibel-Palade Bodies were competent for rapid exocytosis, 
I exposed the iPSC endothelial cells to histamine and measured cell surface expression of another Weibel-
Palade Body constituent, P-Selectin via immunofluorescence. I observed rapid and transient presentation 
of P-Selectin to the cell surface (Figure 3.6E). These observations are particularly important for the 
potential of iPSC endothelium to be used in the human body as a cell based therapy and also for the 
potential application to modeling diseases, in particular the von Willebrand Disease class of hemophilias 
caused by mutations in the vWF gene.  
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Figure 3.6 | (A) Immunofluorescent staining of (A) vWF and (B) 
angiopoietin-2. (C) Transmission electron micrograph of an electron-
dense striated structure resembling a Weibel-Palade Body. (D) 
Electron micrograph with vWF-immunogold labeling of a Weibel-
Palade Body. (E) Surface expression of P-Selectin after 10µm 
histamine treatment. Data are normalized to reading at 0 min and 
shown as mean ± s.d.. * indicated statistically different means 
compared to 0 min with p < 0.05, n=4.  
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3.3 | Assessment of endothelial activation 
 
After observing several molecular and behavioral features of mature vascular endothelium within 
the iPSC derived endothelial cells above, I investigated whether iPSC derived vascular endothelium can 
display the multiple functional phenotypes characteristic of mature endothelium. A pathophysiologically 
essential property of the endothelium is to respond to pro-inflammatory stimuli and participate in 
inflammatory response. In response to pro-inflammatory stimuli, the endothelial cells can adopt an 
activated phenotype characterized by the secretion of pro-inflammatory cytokines and chemoattractants 
and presentation of leukocyte adhesion molecules at its surface70,71,72,73. This coordinated response can 
promote the interaction of monocytes, neutrophils, and T cells and the vascular wall mediating many 
inflammatory processes.  
To assess whether iPSC derived endothelial cells are capable of exhibiting this functional 
phenotype, I exposed iPSC endothelial cells to several pro-inflammatory stimuli, namely interleukin-1 
beta (IL1β), tumor necrosis factor alpha (TNFα) and lipopolysaccharide (LPS), and assessed the cell 
surface expression of the adhesion molecules E-Selectin, intercellular adhesion molecule 1 (ICAM-1) and 
vascular cell adhesion molecule 1 (VCAM-1), all critical for endothelial-leukocyte interactions (Figure 
3.7A). Treatment with IL1β, TNFα or LPS for 6 hr induced the expression of E-selectin and ICAM-1 in 
the majority of the cell population, and of VCAM-1 in a fraction of the population. After 24 hr of IL1β, 
TNFα or LPS stimulation, the iPSC endothelial cells expressed E-Selectin to a lesser degree, and ICAM-1 
and VCAM-1. The temporal difference in expression of E-Selectin, ICAM1 and VCAM-1 are similar to 
those observed in primary human endothelial cells. Additionally, treatment with interferon-gamma (IFNγ) 
induced the iPSC endothelial cells to upregulate ICAM-1 expression synergistically with TNFα in a time-
dependent manner (Figure 3.7B) as reported in studies of primary endothelial cell cultures74. 
In addition to presenting adhesion molecules, the activated endothelial phenotype is characterized 
by secretion of pro-inflammatory cytokines responsible for attracting immune cells. Therefore, I 
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examined whether iPSC endothelial cells have this capability by measuring the concentration of several 
pro-inflammatory cytokines in the culture supernatant in response to pro-inflammatory activation. 
Treatment for 24 hr with IL1β, TNFα or LPS induced the iPSC-EC to secrete monocyte chemotactic 
protein-1 (MCP1), interleukin-8 (IL8), RANTES and interferon-gamma-induced protein 10 (IP10), potent 
chemoattractants that act on T cells, neutrophils and monocytes, into the cell culture supernatant which I 
measured by cytometric bead assay (Figure 3.8). Additionally, treatment with interferon-gamma (IFNγ) 
induced the iPSC endothelial cells to secrete IP10 and monokine induced by gamma interferon (MIG). 
Importantly, the coordinated expression of leukocyte adhesion molecules and secretion of pro-
inflammatory cytokines by the vascular endothelium orchestrates the transendothelial migration of 
leukocytes. Given that the iPSC derived endothelial cells exhibited inducible leukocyte adhesion 
molecule surface expression and secretion of pro-inflammatory chemoattractants, I investigated whether 
these endothelial cells are also able to support interaction with leukocytes. After stimulating the iPSC 
endothelial cells with 4 hr treatment with TNFα, I observed that they were able to coordinate the 
integrated behavior of inducing human neutrophil and T lymphocyte rolling, arrest, and transmigration 
under laminar fluid flow (Figure 3.9A and B). The kinetics and fraction of transmigrating leukocytes 
were comparable to those seen with primary umbilical vein EC, the in vitro human model currently most 
commonly used for leukocyte transmigration studies (Figure 3.9C-E). 
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Figure 3.7 | (A) Surface expression of E-Selectin, ICAM-1 and 
VCAM-1 after 6 or 24 hr treatment with 10 U/mL IL1β, 10 ng/mL 
TNFα or 1 µg/mL LPS measured by flow cytometry. (B) Surface 
expression of E-Selectin, ICAM-1 and VCAM-1 after 4, 24 or 48 hr 
treatment with 10 U/mL IL1β and 10 ng/mL TNFα alone or in 
combination. Flow cytometry data are representative of three 
independent experiments. 
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Figure 3.8 | Culture supernatant concentration of MCP1, IL8, 
RANTES, IP10 and MIG after 24 hr treatment of 10 ng/mL TNFα, 
10 U/mL IL1β, 10 ng/mL IFNγ, 1 µg/mL LPS or 10 ng/mL TNFα + 
10 ng/mL IFNγ measured by cytometric bead assay. Pooled data are 
represented as mean ± s.d. with * indicating statistical significance 
compared to vehicle tested by ANOVA with p<0.05, n=3-6. 
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Figure 3.9 | Transmigration of a human (A) neutrophil and (B) T cell 
through a monolayer of iPSC endothelial cells. (C) Fraction of 
transmigrated neutrophils and T cells on HUVEC and iPSC 
endothelium after 10 min. Time profile of transmigrated (D) 
neutrophils and (E) T cells after 4 hr 10 ng/mL TNFα treatment. In 
all panels, pooled data are represented as mean ± s.d., n=3-4 
independent experiments with three replicates for each experiment. 
  
36 
 
3.4 | Measurement of dynamic barrier response 
 
 An important function of the vascular endothelium is to form a tight dynamic barrier to contain 
the blood’s plasma and cellular constituents. Endothelial cells actively rearrange junctional and 
cytoskeletal proteins to modulate their barrier function in response to multiple physiological stimuli75,76. 
To characterize the barrier phenotype of iPSC endothelial cells, I examined the role of known modulators 
of endothelial permeability on the electrical resistance across a monolayer of cultured iPSC endothelium, 
a real time measure of permeability. As seen in Figure 3.10A, the inflammatory mediator histamine 
induced a transient increase in permeability while VEGF induced a sustained increase in permeability. 
Prostaglandin E2, found at sites of inflammation, produced a decrease in permeability as did sphingosine-
1-phosphate, which is produced by activated platelets. cAMP elevation and the subsequent activation of 
Epac proteins, which are cAMP-responsive guanine exchange factors for Rap GTPase, have been shown 
to decrease permeability of endothelial monolayers77. Treatment of iPSC endothelial cells with the cAMP 
analogue, 8-pCPT-2’O-Me-cAMP (O-Me) that selectively activates Epacs77, induced a sustained decrease 
in permeability as reported in primary EC78. I next documented rearrangements of structural proteins that 
modulate barrier properties76. As seen in Figure 3.10B, I found that treatment with O-Me resulted in 
redistribution of VEC from a jagged to a more linear geometry and favored the generation of cortical 
actin over longitudinal stress fibers, as previously described in primary vascular endothelium78. These 
results suggest that iPSC derived endothelium may be a model system to study the effects of endothelial 
genetic contributions to vascular permeability. 
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Figure 3.10 | (A) Changes in transendothelial electrical resistance 
after treatment with 10 µM histamine, 100 ng/mL VEGF, 200 ng/mL 
prostaglandin E2, 0.5 µg/mL sphingosine-1-phosphate or 100 µM O-
Me. Traces are represented as mean ± s.d., n=3. (B) Rearrangements 
of VEC or actin after 24 hr treatment with 100 µM O-Me seen by 
immunofluorescence. 
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3.5 | Characterization of biomechanics-induced atheroprotected and atheroprone phenotypes 
 
One of the exciting putative applications of iPSC derived vascular endothelium is the ability to 
model endothelial function and dysfunction in a patient specific manner. A fundamental aspect of 
endothelial function and dysfunction involves the endothelial response to mechanical stimulation 
providing by flowing blood, or hemodynamics. Interestingly, distinct local hemodynamic environments 
have been linked to the nonrandom predictable distribution of atherosclerotic lesions in human and animal 
studies79-81. In fact, local biomechanical forces can strongly influence endothelial phenotype and can 
induce a functional phenotype or one that is dysfunctional, a state seen as an early step in atherogenesis82-
85. In particular, it has been previously shown that the specific shear stress patterns exerted on endothelial 
cells at the sites of atheroresistance, such as in the distal internal carotid artery, and atherosusceptibility, 
as in the carotid sinus in the human carotid artery induce “atheroprotective” and “atheroprone” cellular 
phenotypes respectively in cultured endothelial cells86. Therefore, I sought to determine whether similar 
biomechanical stimuli are able to evoke these characteristic biomechanically-induced phenotypes in iPSC 
endothelial cells. To investigate this, I exposed the cells to atheroprotective or atheroprone shear stress 
waveforms for 72 hr. As seen in Figure 3.11A and B, the endothelial cells selectively responded to the 
atheroprotective flow by aligning in the direction of flow while those exposed to atheroprone flow did 
not. Single periods of the atheroprotective and atheroprone shear stress waveforms derived from the sites 
of atheroresistance or atherosusceptibility in the human carotid are provided in Figure 3.11C. A key 
molecular descriptor of the endothelial atheroprotective versus atheroprone phenotype is the expression of 
the transcription factors Kruppel-like factor 2 (KLF2) and 4 (KLF4), integrators of the flow-mediated 
vasoprotective phenotype87-90. I measured the expression of these genes in iPSC endothelial cells exposed 
to atheroprotective or atheroprone shear stress waveforms and observed that the atheroprotective 
waveform differentially induced the expression of KLF2 and KLF4 (Figure 3.11D). Furthermore, I 
measured the expression of several other mechano-activated genes and downstream effectors of KLF2 
and KLF4 and observed that atheroprotective shear stress upregulates eNOS, argininosuccinate synthase 1 
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(ASS1), and down-regulates vWF. In contrast, atheroprone flow increased the expression of endothelin-1 
(ET1), a potent vasoconstrictor as previously described to be differentially regulated by flow87. These data 
indicate that iPSC endothelial cells are able to respond to distinct biomechanical stimuli and adopt an 
atheroprotective or atheroprone phenotype. This recapitulated capability may enable new studies of 
patient specific endothelial function and dysfunction relevant to atherogenesis.  
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Figure 3.11 | . iPSC endothelial cells seen by phase contrast after 72 
hr of (A) atheroprone or (B) atheroprotective flow (arrow indicates 
direction of flow). (C) A single period of atheroprotective and 
atheroprone shear stress waveforms. (D) 72 hr of atheroprotective 
shear stress upregulates gene expression of KLF2, KLF4, eNOS, 
ASS1, and downregulates vWF as atheroprone shear stress 
upregulates ET1. Pooled data are normalized to expression under 
static conditions and represented as mean ± s.d. with * indicating 
statistical significance with p<0.05, n=4. 
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3.6 | Evaluation of pharmacologically induced atheroprotection 
 
An exciting potential application of iPSC derived vascular endothelium is their ability to serve as 
a personalized substrate for pharmacological testing. It is known that endothelial cell phenotype is 
sensitive to several widely used pharmacological agents such as cyclooxygenase-2 inhibitors, PPAR 
modulators and statins91,92. I sought to examine whether iPSC endothelium is similarly sensitive to one 
such drug to indicate whether iPSC endothelial cells may be a surrogate to study drug induced vascular 
effects. Specifically, it has been documented that the expression of KLF2 and an endothelial 
atheroprotective phenotype can be evoked by a pleiotropic effect of the statins, a class of HMG-CoA 
reductase inhibitors93,94. Therefore, I examined whether iPSC endothelial cell phenotype can be similarly 
modulated by statin treatment. As seen in Figure 3.12, simvastatin upregulated atheroprotective KLF2 
expression as well as several downstream effectors such as eNOS, ASS1, thrombomodulin (TM), integrin 
beta 4 (INTB4), prostaglandin-H2 D-isomerase (PTGDS). Simvastatin also led to the down-regulation of 
pro-inflammatory angiopoietin-2 (ANGPT2) and vasoconstrictor ET1. Furthermore, the induction of 
KLF2 and eNOS in iPSC derived endothelial cells showed similar sensitivity to simvastatin concentration 
(1-10 µM) as primary endothelial cells (Figure 3.13). This data suggests that iPSC derived endothelium 
serves as a faithful model of at least the endothelial atheroprotective cellular phenotype induced by 
statins. 
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Figure 3.12 | (A) Induction of atheroprotective genes and down-
regulation of atheroprone genes in iPSC endothelial cells in response 
to 24 hr of 10µM simvastatin measured by qRT-PCR. Data are 
normalized to expression in response to vehicle and plotted with 
error bars equal to s.d. * indicates significant statistical difference 
from vehicle with p < 0.05, n=4. 
 
 
 
 
 
Figure 3.13 | (A) Induction of KLF2 and eNOS gene expression 
measured by qRT-PCR in response to 24 hr treatment with varying 
doses of simvastatin in HUVEC and iPSC endothelial cells. Data are 
represented as means ± s.d., n=4-6. 
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4 | Arterial and venous identities within human induced pluripotent stem 
cell derived vascular endothelium 
 
Human vascular endothelium is a heterogeneous set collection of distinct cellular subtypes. These 
vascular endothelial identities vary by their anatomical location such as in the context of arterial, venous 
or capillary endothelium, residence in micro, small, or large vessels, or association with other organs such 
as the glial cells in blood brain barrier endothelium, hepatocytes in liver sinusoidal endothelium or 
podocytes in glomerular endothelium. In the previous experiments, I considered the iPSC derived 
vascular endothelium as a single population of undefined identity; however, in the following experiments, 
I sought to evaluate whether the iPSC derived vascular endothelium could be directed to an arterial or 
venous fate and whether there was any existing molecular heterogeneity from the embryoid body derived 
cells suggesting an arterial or venous identity. This line of investigation is essential for future applications 
of iPSC where genetic diseases manifest selectively in arterial or venous endothelium, or for cell-based 
assays of endothelial function which is known to vary between different endothelial subtypes. 
 
4.1 | Biomechanical specification to arterial and venous identities 
 
There are numerous lines of evidence indicating that the local biomechanical environment of 
vascular endothelial cells plays an important role in establishing the arterial or venous fate of the 
endothelium as elaborated in Section 1.2. I wished to examine whether iPSC derived vascular 
endothelium could similarly display an arterial or venous identity sensitive to its biomechanical 
environment. To assess this, I applied two different shear stress waveforms to the cultured iPSC 
endothelial cells; one derived from the shear stress applied to the wall of the human abdominal aorta and 
one from the human saphenous vein. These arterial and venous waveforms, of which individual periods 
are plotted in Figure 4.1A, were applied to the cells for 72 hr. After these conditions, I assayed the 
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identity of the endothelial cells by measuring the expression of a panel of genes which are differentially 
expressed on arterial and venous endothelial cells. I observed that the arterial shear stress condition 
upregulated expression of notch4, hey1, hey2, ephrinB2 and ephB4, endomucin and VEGF and down-
regulated expression of delta-like ligand-1, jagged1, angiopoietin-2, and vWF. Alternatively, venous 
shear stress upregulated expression of EphB4 and endomucin. These gene expression signatures30-33 
suggest that arterial and venous shear stress environments in vitro are able to guide iPSC endothelium 
towards an arterial and venous fate, respectively. Interestingly, endomucin, which is typically expressed 
to a greater extent on venous endothelium than arterial endothelium95, is upregulated by both arterial and 
venous shear stress in cultured iPSC endothelium. It is also interesting to note that arterial flow down-
regulated expression of vWF, which is known to be expressed to a greater degree on venous 
endothelium96 and also known to contribute to atherogenesis in a hemodynamic-environment dependent 
manner97. These results suggest that iPSC derived vascular endothelium exhibits an identity sensitive to 
biomechanical stimulation which is able to be guided to arterial or venous fate as indicated by gene 
expression by different flow waveforms. 
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Figure 4.1 | (A) A single period of arterial and venous shear stress 
waveforms. (B) Gene expression of arterial and venous markers in 
iPSC hEC. Pooled data are represented as means ± s.d., n=4. * 
indicates p<0.05 comparing expression of each gene to the static no 
flow condition. 
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4.2 | Genetic specification to arterial and venous identities 
 
During embryonic development, arteries and veins form lined with vascular endothelial cells with 
distinct molecular identities, as mentioned in section 1.2. Despite the influence of biomechanical forces 
on arterial and venous identity, the initial adoption of arterial and venous fate occurs prior to the onset of 
circulation in the developing organism43,45. This observation suggests that developmental pathways 
specified by genetic programs are sufficient to establish unique arterial and venous endothelial subtypes. 
Thus, if genetic specification alone is able to give rise to distinct vascular endothelial subtypes during 
development in the absence of hemodynamic environments, it is possible that pluripotent stem cells are 
also able to differentiate into arterial and venous endothelial cells in vitro. Hence, I investigated whether 
the iPSC derived differentiating embryoid bodies can also produce arterial and venous subtypes of 
vascular endothelial cells as diagramed in Figure 4.2. 
 
Figure 4.2 | Illustration of the process of generating subtype specific 
endothelial cells from patient tissue samples via induced pluripotent 
stem cells. 
To assess this, it is necessary to separate arterial and venous endothelial cells from the 
heterogeneous embryoid bodies. Extensive previous work has identified the molecular signatures that 
define arterial and venous endothelial cells (as previously reported30-33). The protein and gene expression 
constituting such signatures are generally not mutually exclusive, i.e. both arterial and venous endothelial 
cells tend to express the same markers though to differing magnitudes. However, the best characterized 
marker of arterial fate, the transmembrane ligand ephrinB2, is exclusively expressed on arterial 
endothelial cells and absent in venous endothelial cells in both embryonic44 and post-natal98 vasculature. 
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The cognate receptor for ephrinB2, ephB4 is exclusively expressed on venous endothelial cells during 
embryonic development; however this exclusivity is lost during development as both arterial and venous 
endothelial cells gain ephB4 expression44,98. A potential strategy to separately isolate arterial and venous 
endothelial cells from the embryoid body would be to sort cells expressing VE-Cadherin and also sort the 
ephrinB2 positive and negative populations which would represent arterial and venous endothelial cells 
respectively. However, flow cytometry was not able to resolve ephrinB2 expression using two different 
anti-ephrinB2 antibodies. The lack of high quality antibodies against ephrinB2 has been commented on 
previously99. Other groups have identified the chemokine receptor CXCR4 as another surface marker of 
arterial endothelial cells. CXCR4 has been shown to be selectively present in arterial vasculature as in 
zebrafish anterior (but not posterior) lateral dorsal aortae100, in the murine dorsal aorta but absent in the 
cardinal veins of the aorto-gonado-mesonerphros region of the mouse embryo101, in the developing 
mesenteric arteries of the small intestine also in the mouse embryo102 as well as in the developing 
arterioles of murine skin103. Studies in the zebrafish have shown that once connection with the arterial 
network and perfusion through new arteries commences that CXCR4 expression is lost104. This is 
corroborated by the fact that shear stress applied to cultured endothelial cells also downregulates CXCR4 
expression105. Generally, it is believed that interaction between CXCR4 and its ligand CXCL12 (also 
known as SDF-1) contributes to vessel patterning106. Previously, other groups have used CXCR4 as a 
marker of arterial endothelial cells when segregating embryoid bodies derived from mouse embryonic 
stem cells101,107. Thus, I examined expression of CXCR4 within the human iPSC derived differentiating 
embryoid bodies. When examining CXCR4 and VEC expression in dissociated embryoid bodies, it is 
clear that there are four populations (Figure 4.3, left panel). When visualizing only the VE-Cadherin 
expressing cells, a VE-Cadherin+|CXCR4+ population is resolved (Figure 4.3, center panel). After 
repeating this observation, rather consistently 35% ± 3% (mean ± s.d.) of the endothelial cells within the 
embryoid body express CXCR4 and are likely of arterial identity (Figure 4.3, right panel). 
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Figure 4.3 | Flow cytometry analysis of CXCR4 and VE-Cadherin 
expression showing VEC+|CXCR4+ and VEC+|CXCR4- populations 
(left and center, dotted trace is a matching isotype control). The 
fraction of VEC+ cells which express CXCR4 is reproducible (right). 
Flow cytometry plots are representative. Pooled data are 
represented as means ± s.d., n=6. 
 
 
Following observation that there exists a reproducible subpopuation of embryoid body derived 
endothelial cells expressing CXCR4, I wished to evaluate whether this subpopulation more closely 
resembles arterial endothelium as would be expected from published data. To do this, I used fluorescence 
assisted cell sorting to isolate live VEC+ and CXCR4+ or CXCR4- cells from embryoid bodies and 
measured the expression of a panel of genes associated with arterial identity (Figure 4.4). The CXCR4+ 
subfraction of VEC+ endothelial cells expressed statistically significant greater ephrinB2, hey2, notch4, 
connexin-40 (Cx40, also known as ZO-1), connexin-37 (Cx37) and tissue plasminogen activator (tPA). 
As expected, there was no significant differnece in expression of VEC or β-actin between the CXCR4± 
subfractions. Interestingly, there also was no significant difference in the expression of vWF, despite the 
fact that it is known to be differentially expressed in arterial and venous endothelium as mentioned above. 
These results suggest that there does exist molecular heterogeneity among the VEC+ endothelial cells 
derived from iPSC with arterial and venous identity polarized along an axis of expression of CXCR4. It is 
noteworthy that this molecular distinction between these arterial and venous subtypes exists in the 
complete absence of any biomechanical stimulation in the history of these endothelial cells, a feature not 
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shared with other in vitro models of endothelial cell biology where cells are derived from vessels which 
have harbored blood flow at some point in their natural history.  
 
 
 
Figure 4.4 | Expression of genes in VEC+|CXCR4+ and 
VEC+|CXCR4- populations. Pooled data are represented as means ± 
s.d., n=4. * indicates p<0.05 comparing expression of each gene 
between populations. 
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4.3 | Assessing the origin of the arterial/venous differential expression of vWF  
 
Due to the preponderance of evidence that arterial and venous identities are guided by genetic 
programs during embryonic development but with sufficient plasticity to be sensitive to their local 
hemodynamic environment, it is likely that some attributes of the mature arterial and venous identity may 
be attributable to their genetic ontogeny, others to the biomechanical environment and some responsive to 
both. Endothelium derived from iPSC offer a unique model system of endothelial cell development as the 
first onset of hemodynamic stimuli can be experimentally controlled. In particular, these results regarding 
arterial and venous identity (Figure 4.4) show that while there is a clear molecular distinction between 
the arterial CXCR4+ and venous CXCR4- subsets of endothelial cells in terms of expression of arterial 
specific genes ephrinB2, notch4, hey2, cx40, cx37, and tPA there is no differential expression of vWF in 
contrast to what is expected based upon in vivo observations. However, arterial biomechanical stimulation 
applied to the pooled CXCR4± populations induced a down-regulation of vWF, reconstituting the subtype 
specific expression pattern (Figure 4.1). This suggests that the differential expression of vWF observed in 
arterial and venous endothelial cells is a consequence of their biomechanical environments rather than 
their genetic ontogeny. To better define this process and to evaluate whether one of the CXCR+ or 
CXCR4- subsets is specifically responding to the arterial shear stress, I sought to perform a similar 
experiment but with isolated purified VEC+|CXCR4+ and VEC+|CXCR4- populations independently. 
Purification of these populations based on expression of two cell surface markers presented a new 
challenge as the magnetic bead based purification methodology is only able to positively select cells in a 
binary fashion based on a single molecular criterion. To address this, I experimented with a commercial 
product offering enzymatic dissociation magnetic bead conjugated antibodies (Miltenyi) with the goal of 
performing two serial magnetic bead based positive selection sorts. However, sorting with this system, 
either for VEC then CXCR4 or vice versa, produced low yields and poor purity in the final isolated 
populations (<50%). The performance of this methodology is clearly not viable for downstream 
applications. Following this, I turned to sorting with fluorescence based cell sorting (FACS). At the outset 
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of the iPSC endothelial cell isolation experiments described in Section 2.2. I attempted to isolate the 
VEC+ cells with FACS following embryoid body dissociation. However, in comparison to magnetic bead 
sorting, FACS isolation produced poor survival leading me to use magnetic bead based separation for the 
experiments described in Section 3. Now, with the necessity of sorting based on two antigens, I altered 
some of the machine parameters of the FACS isolation, opting for an increased size of nozzle from 70µm 
to 100µm, slowing the fluid stream velocity, lowering the sheath pressure, minimizing vortexing and 
maintaining the cell slurry at 4°C. These conditions significantly improved survival and permitted 
isolation of monolayers of VEC+|CXCR4± populations as seen in Figure 4.5. 
 
 
Figure 4.5 | Phase contrast images of the CXCR4+ and CXCR4- 
purified subsets of VEC+ iPSC endothelial cells after FACS 
isolation. 
 
 
Using these conditions, I sought to use purified isolated VEC+|CXCR4+ and VEC+|CXCR4- 
populations and independently examine the expression of vWF in each population after exposure to 
arterial and venous shear stress regiments or static conditions. This experiment is schematically outlined 
in Figure 4.6, where VEC+|CXCR4+ and VEC+|CXCR4- endothelial cell populations are isolated from 
embryoid bodies by FACS, then cultured independently under static conditions for 3 days allowing 
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formation of a confluent monolayer, and then exposed to 3 days of either arterial, venous or static flow 
conditions in vitro as previously shown in Figure 4.1. Following the arterial biomechanical stimulation, it 
was apparent that both VEC+|CXCR4+ and VEC+|CXCR4- endothelial cell populations elongated and 
aligned in the direction of flow as seen in Figure 4.7. I also observed that arterial biomechanical 
stimulation resulted in about half the magnitude of vWF gene expression as observed after static or 
venous shear stress. This arterial shear stress mediated down-regulation of vWF expression was observed 
to an equal degree in both VEC+|CXCR4+ and VEC+|CXCR4- endothelial cell populations. These 
observations suggest that the biomechanical environment, not the genetic ontogeny, is responsible for the 
differences in vWF expression observed in the vascular tree. 
 
 
 
 
Figure 4.6 | Schematic representation of the experiment involving the 
FACS isolation of VEC+|CXCR4± cells, static culture for 3 days and 
subsequent exposure to arterial, venous or static conditions for 
another 3 days after which RNA is harvested. 
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Figure 4.7 | Phase contrast images of CXCR4+/- hEC after static, 
arterial flow or venous flow conditions. 
 
 
 
 
Figure 4.8 | Gene expression of vWF in CXCR4+/- hEC after static, 
arterial or venous flow conditions. 
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5 | Methods 
 
5.1 | Human induced pluripotent stem cell culture and differentiation  
 
Human iPSC were cultured as previously reported108, on irradiated mouse embryonic fibroblasts 
(GlobalStem, Rockville, MD) and passaged mechanically. Four human iPSC lines were used. Lines BJ1 
and MSC1 were received from the laboratory of Dr. George Q. Daley (Children’s Hospital Boston), line 
BMC1 in the laboratory of Dr. Darrell N. Kotton (Boston University Medical Center) and line DH1F 
from the Harvard Stem Cell Institute. All lines were created by overexpression of reprogramming genes 
OCT4, SOX2, KLF4 and CMYC though reprogrammed through different technologies. Line BJ1  was 
created with 4 retroviruses from human dermal fibroblasts109. MSC1 was created with 4 retroviruses from 
human mesenchymal stem cells109. BMC1 was created with a single lentivirus from human dermal 
fibroblasts110. DH1F was created with modified-RNAs from human dermal fibroblasts111. The BJ1 iPSC 
line was used for detailed functional characterization of the derived EC. 
 
Human iPSC medium consisted of DMEM:F12 (Invitrogen, Life Technologies, Carlsbad, CA), 
20% Knock Out Serum Replacement (Invitrogen), 5 ng/mL bFGF (Miltenyi, Bergisch Gladbach, 
Germany), 110 µM 2-mercaptoethanol (Sigma, St. Louis, MO), 100 µM non-essential amino acids 
(Invitrogen), 50 ng/mL ascorbic acid (Sigma), and 125 U/mL penicillin and 125 µg/mL streptomycin 
(Lonza, Basel, Switzerland). Differentiation medium consisted of DMEM, 20% fetal calf serum (Gemini 
Bio-Products, West Sacramento, CA), 2 mM L-glutamine (Invitrogen), 110 µM 2-mercaptoethanol 
(Sigma), 100 µM non-essential amino acids (Invitrogen), 50 ng/mL ascorbic acid (Sigma), and 125 U/mL 
penicillin and 125 µg/mL streptomycin (Lonza). Endothelial cell medium consisted of M199 (Lonza), 
20% fetal calf serum, 2 mM L-glutamine, 50 µg/mL EC growth supplement (Sigma), 100 µg/mL heparin 
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(Sigma), 100 µM non-essential amino acid solution, and 125 U/mL penicillin and 125 µg/mL 
streptomycin. 
 
5.2 | Culture of human umbilical vein endothelial cells 
 
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords, pooled, 
and cultured as described previously93 by the cell culture core laboratory of the Center for Excellence in 
Vascular Biology at the Brigham and Women’s Hospital. 
 
5.3 | Transmission electron microscopy and immunogold labeling 
 
Samples were fixed in 4% paraformaldehyde and 0.1% glutaraldehyde for 1 hr and were 
processed by the Harvard Medical School Electron Microscopy Facility. Samples were examined on a 
TecnaiG2 Spirit BioTWIN mission electron microscope with images recorded with an AMT 2k CCD 
camera. Immunogold labeling used a rabbit anti-human vWF antibody (#A008202, Dako, Glostrup, 
Denmark) with protein A conjugated to gold particles of 25 nm diameter. 
 
5.4 | Biomechanical stimulation with shear stress in vitro 
 
In the course of the experiments mentioned above, various biomechanical stimulation regiments 
were used. Specifically, time-varying waveforms replicating the shear stress present on the endothelial 
surface within the distal human internal carotid artery (“atheroprotective”), carotid sinus (“atheroprone”), 
abdominal aorta (“arterial”) or saphenous vein (“venous”) were measured from human subjects and 
applied to iPSC-EC using a custom cone and plate dynamic flow system as reported86,112. 
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5.5 | Transendothelial migration of leukocytes 
 
Human neutrophils and T cells were isolated as previously reported113.  The interaction of 
leukocytes and iPSC-EC was assessed in a custom flow chamber as previously reported113. Briefly, iPSC-
EC were treated with 25 ng/mL TNFα for 4 hr prior to both transmigration assays and additionally 50 
ng/mL SDF-1α for 15 min prior to the T cell transmigration assay. 
 
5.6 | Measurement of endothelial permeability properties 
 
Measurements of electrical resistance across the EC monolayer were performed as previously 
reported78 with an impedance sensor system (Applied Biosystems, Life Technologies, Carlesbad, CA).  
Data were normalized as the ratio of measured to baseline resistance.  
 
5.7 | In vitro angiogenesis assay 
 
The in vitro angiogenesis assay was performed as previously described114. Briefly, basement 
membrane extract (Trevigen, Gaithersburg, MD) was incubated on multiwell culture plates for 1 hour at 
37°C after which iPSC derived endothelial cells were seeded at 20,000 cells/cm2 then observed after 6 hr 
of culture. Cells were grown in EC medium with reduced fetal bovine serum (2%) and reduced 
endothelial cell growth supplement (2.5 µg/mL). 
 
5.8 | RNA extraction, isolation and quantitative real-time PCR 
 
Total RNA was extracted using the Nucleic Acid Purification Lysis Solution, isolated with 6100 
Nucleic Acid PrepStation and eluted into 80µL and then reverse transcribed into cDNA with a High 
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Capacity RNA to cDNA Kit in a Verite thermocycler, all according to the manufacturer’s (Applied 
Biosystems) protocols. Quantitative TaqMan real time polymerase chain reactions (qRT-PCR) were 
performed in 10µL in 384-well format on a 7900HT sequence detection system (Applied Biosystems) 
with TaqMan primers and fluorescent probes provided by Applied Biosystems. 
 
5.9 | Immunofluorescence and imaging 
 
Endothelial cells in culture were washed with warmed PBS+, fixed in warmed 4% 
paraformaldehyde for 5 min, permeabilized in 0.5% Triton X-100 in PBS for 5 mins, blocked with PBS+ 
with 15% fetal bovine serum for 30 mins and then incubated with primary antibody for 2 hr at room 
temperature.  After three washes with PBS they were incubated with secondary antibodies for 1 hr at 
room temperature.  Immunofluorescent labeled cells were visualized on a Nikon TE2000 fluorescence 
microscope and captured with a Hamamatsu CCD camera. Mouse anti human primary antibodies against 
eNOS (# 610296 BD Biosciences), VE-Cadherin (#560410 BD Biosciences), CD31 (#555445 BD 
Biosciences), and a rabbit anti human vWF (#A008202, Dako), angiopoietin-2 (#AF623 R&D Systems) 
were used.  Goat anti-mouse or rabbit Alexa 488 and Alexa 546 were used as secondary antibodies 
(Invitrogen). 
 
P-selectin surface expression was assessed similarly though without permeabilization, using a 
mouse anti-human P-selectin antibody (#555523 BD Biosciences, San Jose, CA) and fluorescence plate 
reader (M2 Spectramax, Molecular Devices, Sunnyvale, CA).  Fluorescent Dil-acetylated-LDL was 
purchased from Invitrogen. Actin was stained with FITC-phalloidin (Invitrogen). Nuclei were stained 
with DAPI at 10 ng/mL (Sigma). 
 
Whole embryoid bodies were immunofluorescently labeled by gently washing with warm PBS+, 
fixing in warmed 4% paraformaldehyde for 10 minutes, and washing 3 times in PBS+ with 15% fetal 
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bovine serum. The EBs were incubated with primary antibodies against VE-Cadherin and CXCR4 for two 
hours at room temperature then washed 3 times. Following this, they were incubated in secondary 
antibodies and DAPI for 1 hour at room temperature then washed 3 times. After mounting on slides, EBs 
were visualized with a Zeiss 710 laser scanning confocal multi-photon system (Zeiss, Oberkochen, 
Germany). 
 
5.10 | Flow cytometry analysis and sorting. 
 
Cells were lifted from their substrate with Cell Dissociation Buffer (Invitrogen) and blocked with 
PBS containing 10% fetal bovine serum for 20 minutes on ice. Primary antibodies were added to the 
blocking solution for 20 min on ice. Cells were washed and incubated with secondary antibodies if 
necessary for 20 min on ice. After washing, labeled cells were measured by flow cytometry on a BD 
FACSCalibur and analyzed by Flowjo software (Tree Star, Ashland, OR). Mouse IgG1 primary 
antibodies against human VE-Cadherin (FITC or PE conjugated, #560410, #560411 BD Biosciences), 
CD31 (FITC conjugated, #555445 BD Biosciences), CXCR4 (PE conjugated #555947 BD Biosciences), 
KDR (PE conjugated #560494 BD Biosciences), and thrombomodulin (PE conjugated #559781 BD 
Biosciences) were purchased along with appropriate isotype controls. Mouse IgG1 antibodies against 
human E-selectin (H 4/18), ICAM-1 (Hu 5/2) and VCAM-1 (E 1/6) or isotype control (K 16/16) were a 
generous gift of the laboratory of Dr. Michael A Gimbrone Jr and were used with goat anti mouse Alexa 
488 (Invitrogen). To measure the extracellular glycocalyx glycoproteins and carriers, flow cytometry was 
performed with antibodies raised against syndecan-1 (biotin conjugated #ab27362, Abcam, Cambridge, 
MA), syndecan-2 (APC conjugated #FAB2965A, R&D Systems, Minneapolis, MN), syndecan-4 (biotin 
conjugated #BAF2918 Abcam), glypican-1 (biotin conjugated #BAF4519, R&D Systems), CD44 (biotin 
conjugated #555477 BD Biosciences), heparan sulfate (#H1890, US Biological, Salem, MA) or 
chondroitin sulfate (#554275 BD Biosciences). Alexa 488 goat anti mouse IgG2a, or goat anti mouse IgM 
or streptavidin-conjugated Alexa488 (Invitrogen) were used as secondary antibodies as appropriate. 
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5.11 | Measurement of soluble cytokines with cytometric bead assay 
 
Concentrations of soluble IL8, MCP1, RANTES, IP10 and MIG in cell culture supernatants were 
measured using a cytometric bead assay (BD Biosciences) according to the manufacturer’s instructions 
and read on a FACSCalibur flow cytometer (BD Biosciences) after appropriate fluorescent calibration 
and compensation using manufacturer provided beads.  Calibration, compensation, measurement of 
standard curves for concentrations from 10 pg/mL to 2500 pg/mL and fresh preparation of standards were 
performed at each experiment. Cytometric bead assay data were analyzed using Flowjo and Excel 
software. 
 
5.12 | Statistical analysis 
Statistical comparisons were performed using the two-sided non-parametric Mann-Whitney test 
or the two-sided unpaired T Test, if indicated, with Stata software. All pooled data in figures and in text 
are represented as the mean ± standard deviation. For multiple statistical comparisons, the one way 
analysis of variance test with Bonferroni correction was used. On figures, * indicates statistical 
significance with p<0.05. Flow cytometry and immunofluorescence data are representative of at least 
three experiments. 
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6 | Conclusions 
 
6.1 | A new source of human vascular endothelium 
 
In one of the initial reports describing the isolation of primary human endothelial cells in 1974, 
Michael A. Gimbrone Jr. and colleagues remarked5 that “confluent endothelial cell cultures could be 
useful in studying the pathophysiology of endothelial growth.” This introductory report heralded a 
prolific era of new studies discerning of the role of the vascular endothelial compartment in human 
pathophysiology. It is from these ensuing studies that the scientific community has developed its current 
knowledge of the vascular endothelium as a critical member of a distributed organ system, forming a 
single-cell layer lining the luminal face of blood vessels. This system constitutes a multifunctional 
interface with phenotypic plasticity that maintains vascular homeostasis, participates in inflammatory 
responses, triggers thrombosis, regulates vasomotor tone, controls vascular permeability and forms new 
vasculature when demanded. 
Despite the significant progress in defining the pathophysiological role of vascular endothelium, 
human vascular endothelium used in research studies today remains to be sourced from discarded 
pathological, cadaveric or umbilical vessels. The procurement of vascular endothelial cells from such 
sources typically precludes the choice of donor patient and thus genetic background, limiting studies of 
the genotype-phenotype relationship to probe endothelial cell biology in the absence of non-physiological 
genetic manipulation. It would take new scientific advances from the field of embryology to provide the 
technological means to study in vitro vascular endothelial cells with specific genetic backgrounds. 
After another seminal discovery, the first report detailing in vitro culture of mouse embryonic 
stem cells6, Gail Martin contemporaneously noted7 that “the availability of such [pluripotent] cell lines 
should make possible new approaches to the study of early mammalian development.” The development 
of embryonic stem cells and the ensuing evolution of knowledge regarding the differentiation of 
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pluripotent cells into mature cell types introduced a new era for cell biology. Though Martin referred to 
the ability to study development in the context of particular genetic mutations, the differentiation of 
pluripotent cells into mature cell types also established a framework to study human development ex vivo, 
in particular in the absence of the complex milieu of biochemical and biomechanical stimulation inherent 
in the embryo. The repercussions of embryonic stem cell biology stretched beyond the study of 
embryogenesis and developmental programs as embryonic stem cells allowed the study cell types such as 
neurons and cardiac myocytes in the human system previously difficult to procure. While embryonic stem 
cells, first in the mouse, then the human, permitted the generation of vascular endothelium in the 
laboratory independent of securing particular patient donors, the embryonic stem cell system still lacked 
the ability to precisely control the genetic backgrounds of the cell lines. For some time, this would remain 
an impediment to genotype-phenotype studies of vascular development and endothelial cell biology as 
well as the development of new regenerative and personalized therapies. 
This impediment was eventually overcome as new stem cell engineering methods were 
discovered with the ability to create all the diverse mature cell types as can be differentiated from 
embryonic stem cells though with the ability to begin with arbitrary patient donor samples and hence 
genetic backgrounds. The relatively recent discovery of human induced pluripotent stem cells by Shinya 
Yamanaka11 effectively democratized the types of research of envisioned forty years ago by Evans, 
Kauffman and Martin. The discovery of iPSC enables the creation of pluripotent stem cell lines derived 
from living human patients replete with their complex undefined genetic backgrounds. For vascular 
biology, this advance allows for the creation of vascular endothelial cells with an unmodified genetic 
background on demand. While tremendously promising for basic and translational research and for novel 
therapeutic modalities, iPSC derived vascular endothelium remained relatively unexplored and certainly 
not adopted by the mainstream field of vascular biology. I posited that there may exist trepidation in 
adoption of such a novel platform due to the limited characterization of the fidelity, in particular in 
relation to the endothelia-specific functions, within iPSC derived endothelium. Thus, I began my this 
research constituting my Ph.D. dissertation in order to develop a protocol for the isolation of human 
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vascular endothelium from induced pluripotent stem cells, to systematically define the endothelia-specific 
cellular functions and to assess arterial and venous specification within iPSC endothelium. I approached 
this problem with scientific standards grounded from an endothelial cell biology laboratory, intending to 
hold a high bar of scrutiny when assaying the endothelial identity of this new artificial model system. 
In this dissertation, I have generated vascular endothelium from human iPSC and characterized its 
functional repertoire. The methodology to differentiate pluripotent cells into vascular endothelium, by 
inducing differentiation of human iPSC colonies in embryoid body format, was reproducible and robust 
across several iPSC lines created with different technologies. I developed a methodology to dissociate 
these embryoid bodies, to isolate purified vascular endothelium and to establish the conditions to culture 
this endothelium in vitro. After isolation and culture, this endothelium displayed many characteristic 
molecular markers of vascular endothelium. Further, I observed vWF-positive functional Weibel-Palade 
Bodies that could rapidly exocytose to the cell surface in response to a physiological stimulus. These 
results suggest that iPSC derived endothelium exhibits a high molecular fidelity to primary human 
vascular endothelium.  
Due to their promise as a novel in vitro model system for human vascular disease, I assessed 
whether iPSC endothelium is competent for the functional repertoire displayed by primary vascular 
endothelium which is known to be critical in several pathophysiological settings. Specifically, a 
fundamental function of the vascular endothelium is to acquire an activated phenotype and to participate 
in an inflammatory response by recruiting leukocytes to sites of inflammation. I documented that the 
iPSC endothelial cells were responsive to multiple pro-inflammatory stimuli (IL1β, TNFα, LPS and 
IFNγ) and capable of producing an activated pro-inflammatory phenotype that included expression of 
leukocyte adhesion molecules E-Selectin, ICAM-1 and VCAM-1, secretion of pro-inflammatory 
cytokines and support for human neutrophil and T lymphocyte rolling, arrest and transmigration. Another 
critical function of vascular endothelium is to serve as a dynamic barrier between blood and tissues. I 
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observed that iPSC endothelial cell monolayers display a dynamic barrier function capable of adjusting 
transendothelial permeability in response to a panel of physiological stimuli.  
To document another specific function of vascular endothelium for which iPSC derived 
endothelial cells may provide a novel platform for in vitro disease modeling studies, I induced iPSC 
endothelium to acquire specific phenotypes previously implicated in vascular pathophysiology. I 
demonstrated that iPSC endothelial cells have the plasticity to adopt distinct flow-dependent phenotypes, 
namely atheroprotective and atheroprone phenotypes critical for atherosclerosis protection and 
susceptibility80,86. I observed that iPSC derived endothelial cells responded to atheroprotective shear stress 
by activating an atheroprotective gene expression program transcriptionally-mediated by the expression 
of the transcription factors KLF2 and KLF4.The expression of these transcription factors has been shown 
to integrate the flow-mediated endothelial atheroprotective functional phenotype by regulating leukocyte 
adhesion, redox state and thrombotic function in cultured human EC87-89,115-117. The ability to direct the 
acquisition of flow-dependent functional and dysfunctional phenotypes using patient-specific 
endothelium should allow the study of specific genetic contributions to endothelial function and 
dysfunction in the context of human cardiovascular disease. 
Another application of patient-specific endothelium capable of modeling functional and 
dysfunctional phenotypes is the evaluation of the effects of pharmacological agents on endothelial cells. I 
demonstrated that treatment of iPSC endothelial cells with simvastatin activated an atheroprotective gene 
expression program and down-regulated genes associated with an atheroprone phenotype. This suggests 
that iPSC endothelial cells may be a suitable surrogate to assess the effects of drugs on the endothelia of 
specific patients. 
In this dissertation, I also sought to investigate the ability of iPSC derived vascular endothelium 
to adopt arterial and venous identities. One stimulus known to affect endothelial identity is biomechanical 
stimulation, in particular shear stress. I demonstrated that the application of shear stress derived from an 
arterial as opposed to that from a venous environment selectively induced the expression of a set of genes 
that are specifically enriched in arterial endothelium. Further, I observed that as iPSC differentiate within 
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embryoid bodies, they produce a heterogeneous population of endothelial cells. Based on upon previously 
published work identifying CXCR4 as an antigen able to distinguish arterial and venous endothelium, I 
observed that CXCR4 expression also distinguished endothelial subpopulations enriched for gene 
expression signatures indicating arterial or venous identity. Interestingly, the expression of a particular 
gene assayed, vWF, did not follow the anticipated expression pattern between the arterial and venous 
subsets, which are based on previous observations in mice and humans. As it appeared vWF was not 
differentially expressed in the arterial and venous iPSC derived endothelial cells based on genetic 
specification during development at least from the embryoid body system, I isolated these two 
subpopulations of endothelial cells from embryoid bodies to further investigate the mechanisms 
controlling the expression of vWF. I demonstrated that biomechanical stimulation specific to the arterial 
microenvironment repressed expression of vWF in both the arterial and venous endothelial cell 
subpopulations. This indicates that while many molecular aspects of arterial and venous endothelial 
identity are specified by genetic programs during differentiation, a subset of the features differentially 
present in arterial and venous endothelium are responsive to the divergent biomechanical stimuli present 
in arteries and veins. These results indicate that iPSC derived endothelium has the ability to acquire 
arterial and venous identities which may be critical for studying endothelial cell biology. 
Collectively, these results advance human iPSC derived vascular endothelial cells as a novel 
experimental platform to study endothelial biology. This platform has tremendous versatility as it is 
‘personalizable;’ able to produce vascular endothelium from any particular patient or genetic background. 
This dimension of patient-specificity adds a powerful dimension to the original conception of using 
isolated human endothelial cells for in vitro research. This advance is an enabling technology which is 
likely to promote new basic research and clinically translatable efforts as will be mentioned in the 
following section.  
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6.2 | Potential applications of personalized vascular endothelium 
 
The discovery of induced pluripotent stem cells introduces the potential to derive all cell types 
bearing a particular patient’s genetic background. This technology is an enabling platform that will 
empower new resources for drug discovery and personalized medicine. In this context, human iPSC have 
many advantages as a cellular substrate as they are: a) infinitely expandable in their pluripotent state, b) 
able to be cryopreserved, c) bear complete and precise genetic fidelity to the patient donor, d) 
immunocompatible with the patient donor, e) able to be generated from minimally invasive blood or skin 
samples, f) able to be genetically modified ex vivo and g) able to be produced without genome 
modification in xeno-free conditions. Human iPSC have been differentiated into many different cell 
types; however with poor functional characterization118. While iPSC have the biological potential to 
differentiate into every cell type, the salient challenge to widespread use of iPSC-derived tissues is the 
obstacle of robustly and reproducibly recreating embryonic cellular differentiation in vitro to produce 
mature functional cells. An important fraction of the research described in this dissertation seeks to 
provide a detailed functional characterization prerequisite for the widespread adoption of iPSC derived 
vascular endothelium for multiple research settings. 
There is a significant need in both clinical and translational research settings for patient-specific 
vascular endothelial cells. In particular, the availability patient-specific vascular endothelial cells should 
enable: a) human cell-based models of genetic vascular disorders, b) personalized pharmacological 
efficacy and toxicity testing as vascular toxicity is a significant cause of drug candidate attrition119, c) 
cell-based therapies for myocardial infarction and peripheral vascular disease, d) vascularization of 
engineered tissues, e) synthesis of vascular grafts and f) the maintenance of an anti-thrombotic surface for 
medical devices such as stents, hemodialysis machines and extracorporeal membrane oxygenation 
devices. Aside from grafts for vascular bypass, it is not currently possible to harvest sufficient endothelial 
cells from patients for the applications mentioned above. Of the many potential applications of patient-
specific vascular endothelium, two appear to be the most promising and immediate. First, in vitro models 
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of drug induced vascular toxicity can be made to reduce attrition of experimental therapies and to help 
stratify patient populations. For comparison, an analogous to an effort to model drug induced 
cardiotoxicity with human iPSC has recently been reported120. The other promising, potentially 
immediate, and intellectually engaging is the possibility of using iPSC derived endothelial cells as a new 
model system to study the endothelial compartment in the context of genetic disorders. The following 
section outlines some of the potential and challenges that may be confronted in future translational 
disease modeling studies. 
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6.3 | Modeling the endothelial compartment within human genetic disorders 
 
Employing iPSC to generate specific cell types to model a genetic disease presents several 
challenges. Here, one must create an iPSC line derived from tissue from patients presenting with a genetic 
disease of interest. These cells must be reprogrammed and differentiated into the cell type of interest. 
While this must be theoretically possible as the living patient is evidence that the disease-causing genetic 
mutation does not preclude pluripotency and development, there may be challenges efficiently recreating 
this process in vitro in the context of genetic abnormalities. Once a particular cell type with a given 
genetic mutation is produced, the mutation must be shown to be present in the cell type and further to 
have a functional consequence. There has been discussion as to the appropriate experimental control for 
such disease modeling, with the strongest candidate being iPSC lines genetically engineered to be 
isogenic to the disease cell line with the exception of a genetic alteration unraveling the original disease-
causing genetic mutation. There has been some precedent for this genome editing approach with iPSC 
lines using zinc finger nuclease technology121,122 and with transcription activator-like effector 
nucleases123. These technologies create two iPSC lines genetically identical with the exception of a point 
mutation corrected; hence, giving power to the specificity of a phenotype illustrated with the patient iPSC 
derived cells. However, there are many situations where such an approach may be inappropriate or not 
possible. More complex genetic abnormalities such as trisomies, copy number variations and other 
complex chromosomal disorders are not able to be corrected in this fashion. Moreover, one of the 
appealing strengths of iPSC in general is that the particular genetic mutations responsible for an observed 
phenotype known to be hereditary need not even be identified in order to produce iPSC lines and hence 
differentiated progeny bearing that unidentified mutation for further study. In such cases, other 
approaches to create appropriate control comparisons include generating iPSC lines from unafflicted 
siblings or parents which will bear genetic similarity to the disease model cell line. Alternatively, a 
strength-in-numbers approach is possible where iPSC lines are generated from many individuals both 
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healthy and afflicted with a particular disorder with the hope of capturing and perhaps averaging across 
different genetic variation. 
Thus far, there are limited examples of modeling human cardiovascular diseases with iPSC.  In 
particular, two groups have generated iPSC lines from patients with Hutchinson-Gilford Progeria 
Syndrome (HGPS), a genetic premature aging disorder that bears clinical resemblance to physiological 
aging124. Specifically, patients with HGPS develop advanced atherosclerosis, among other pathologies, at 
a young age that frequently gives rise to fatal myocardial infarctions and strokes.  Previously, the study of 
cardiovascular disease within this rare disease population was restricted to studies on primary harvested 
dermal fibroblasts or histological study of cadaveric tissue. Both groups created HGPS iPSC lines and 
differentiated these cells into vascular smooth muscle cells to show modest increased senescence under 
several in vitro conditions suggesting a possible mechanism for the premature vascular disease observed 
in this disorder125,126. 
There are several other examples of genetic disorders where iPSC derived vascular endothelium 
may in the future provide a powerful model to evaluate endothelial function in cell based assays. For 
instance, the results in this dissertation demonstrate that iPSC display in vitro angiogenic potential and 
there are several genetic disorders wherein mutations occurring within angiogenic genes cause vascular 
malformations and disease127. Mutations within VEGFR2 and VEGFR3 genes have been linked to cases of 
infantile hemangioma, a vascular tumor128. Hereditary haemorrhagic telangiectasia is a disorder 
characterized by the presence of arteriovenous malformations, direction connections between arteries and 
veins eclipsing the capillary bed. In some instances, these malformations can lead to hypoxemia, stroke, 
heart failure and fatal hemorrhage. While mutations within genes involved in TGFβ signaling pathways 
such as SMAD4129, endoglin130 and ALK1131, have been identified in patients with hereditary 
haemorrhagic telangiectasia, the pathological mechanisms responsible for the malformations remain 
unclear, complicated by the intricate TGFβ signaling network. Arterial tortuosity syndrome, a disorder 
marked by geometric abnormalities of medium and large arteries, has been shown to be caused by 
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mutation in a glucose transporter132. Mutations within several genes, CCM1-3, are associated with dilated 
capillaries and saccular vascular structures in the brain, termed cerebral cavernous malformations133,134. 
There are numerous other examples of vascular malformations with genetic origins1. In all these 
instances, the creation of a human genetic model through induced pluripotent stem cells coupled with 
assessment of angiogenic potential may elucidate the functional consequences and molecular mechanisms 
behind these vascular malformations. 
 In response to pro-inflammatory stimuli, the vascular endothelium enters an activated phenotype 
characterized by the secretion of pro-inflammatory cytokines and chemoattractants and presentation of 
intercellular adhesion molecules to its surface70,71,72,73. This coordinated response can promote the 
interaction of monocytes, neutrophils, and T cells and the vascular wall mediating many inflammatory 
processes. These elements of endothelial activation, also observed within iPSC derived endothelium as 
observed above, may provide a new in vitro model of inflammatory disease. This leukocyte-endothelial 
interaction has significant consequences for the defense against pathogens, atherosclerosis135,136 and 
autoimmune disorders such as systemic lupus erythematous137, Kawasaki disease138, scleroderma139. 
While many of the specific mediators, chemokines and adhesion molecules, have been identified, the 
signaling mechanisms responsible for these interactions are not fully understood, especially in the context 
of cardiovascular, autoimmune diseases and rare diseases. Frequently, the genetic determinants of the 
endothelial dysfunction in these disorders have not been identified. In this case, iPSC derived 
endothelium presents a system of capturing the genetics of complex human disease without even having 
to identify the particular pathological genetic variation. The interaction of leukocytes and endothelium has 
been studied in vitro under a variety of inflammatory contexts. Here, the biophysical interaction of the 
leukocyte, rolling, slow rolling, arrest, and transmigration, occur amidst specific hemodynamic conditions 
in the vasculature that can be recreated with in vitro flow systems140,141,142. My results suggest that iPSC 
derived endothelium may be an appropriate model system to study the interaction of leukocytes and 
patient-specific endothelium as iPSC endothelial cells were able to adopt an activated phenotype and 
support leukocyte transmigration. 
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 An essential function of the vascular endothelium is to maintain a dynamic and selectively 
permeable barrier regulating the transport of fluid and macromolecules between the circulation and the 
interstitial space. The dynamism of this barrier function is regulated by a variety of soluble factors, cell 
surface receptors, signaling molecules, cytoskeletal and other structural proteins143,76. Vascular endothelial 
permeability is critical for maintaining vascular homeostasis and for access of pharmacological agents to 
cross the specialized blood brain barrier. Further, endothelial permeability contributes to inflammatory 
processes144, dysfunctional vasculature near solid tumors145 as well as in chronic disease states. In 
particular, the advanced glycation end products present in diabetic vasculature have been shown to 
influence endothelial barrier function resulting in vascular hyperpermeability146,147 with several molecular 
mediators identified148. The complex effects of these pathological settings on endothelial permeability can 
be assayed in vitro most commonly either through detection of trans-cellular transport of fluorescently 
labeled macromolecules such as dextran through dual chambered culture devices, or by measurement of 
electrical impedance between microelectrodes across endothelial monolayers149,150. These assays are 
highly quantitative and are able to produce time dependent permeability data able to discern transient 
effects. Miniaturization and parallelization of these assays, both fluorescent-based macromolecule 
transport151 and commercially available 96-well platforms and culture plates for measuring 
transendothelial electrical resistance, permit screening assays to use endothelial permeability as a direct 
functional output. This dimension of vascular homeostasis represents another area where patient-specific 
iPSC derived vascular endothelium may contribute to new translational research. 
It may be that by employing human iPSC derived cells with appropriate genetic background, 
recreating precise physiological environments and by using cell based assays of cellular function, it is 
possible to more faithfully reproduce pathophysiological processes in vitro and offer a more relevant 
human experimental platform for drug discovery. Above, I introduced several vascular endothelial 
functions that the pharmaceutical industry has been able to mimic and miniaturize for at least medium 
throughput experiments which in conjunction with new patient-specific iPSC derived vascular 
endothelium may prove useful for the discovery of new cardiovascular therapies and drug targets. The 
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technology exists to further increase parallelization should industrial rather than academic laboratories 
become more interested in their use. This may be of particular importance in research on orphan and rare 
diseases in which little is known about the molecular basis of the disease and where primary tissue is 
unavailable for study. 
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